Comparative Pharmacology
Head-to-head clinical analysis: ARIMIDEX versus EXEMESTANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIMIDEX versus EXEMESTANE.
ARIMIDEX vs EXEMESTANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aromatase inhibitor; inhibits conversion of androgens to estrogens by binding to aromatase enzyme, reducing estrogen levels in tissues.
Irreversible steroidal aromatase inhibitor; binds to the substrate-binding site of aromatase, causing permanent inactivation of the enzyme. Reduces estrogen synthesis by inhibiting conversion of androgens to estrogens.
1 mg orally once daily
25 mg orally once daily after a meal.
None Documented
None Documented
Terminal elimination half-life ~50 hours (range 30-60 hours); supports once-daily dosing.
Clinical Note
moderateExemestane + Digoxin
"Exemestane may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateExemestane + Digitoxin
"Exemestane may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateExemestane + Deslanoside
"Exemestane may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateExemestane + Acetyldigitoxin
"Exemestane may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing. Steady state is achieved after 7 days.
Primarily hepatic metabolism via N-dealkylation and glucuronidation; ~80% excreted in feces, <10% unchanged in urine.
Primarily hepatic metabolism (CYP3A4 and aldoketoreductases) with fecal excretion of metabolites (approximately 80-90%) and renal excretion of unchanged drug and metabolites (approximately 10-20%).
Category C
Category D/X
Aromatase Inhibitor
Aromatase Inhibitor